Compare PFSA & VTAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PFSA | VTAK |
|---|---|---|
| Founded | 2009 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7M | 1.8M |
| IPO Year | N/A | 2018 |
| Metric | PFSA | VTAK |
|---|---|---|
| Price | $1.71 | $0.26 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.0M | ★ 9.0M |
| Earning Date | 04-15-2026 | 08-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 89.53 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $442,000.00 |
| Revenue This Year | N/A | $1,170.33 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3057.14 |
| 52 Week Low | $0.05 | $0.15 |
| 52 Week High | $4.22 | $4.31 |
| Indicator | PFSA | VTAK |
|---|---|---|
| Relative Strength Index (RSI) | 56.07 | 30.75 |
| Support Level | $0.21 | N/A |
| Resistance Level | $2.25 | $1.12 |
| Average True Range (ATR) | 0.34 | 0.17 |
| MACD | -0.04 | -0.05 |
| Stochastic Oscillator | 2.13 | 1.36 |
Profusa Inc is a clinical-stage digital health and medical technology company. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds that do not heal properly; and reconstructive surgery.
Catheter Precision Inc is engaged in the design, manufacture, and sale of medical technologies focused in the field of cardiac electrophysiology, or EP. The company's two primary products include the VIVO System and LockeT. The VIVO System, which is an acronym for View into Ventricular Onset System(VIVO or VIVO System), is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its newest product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure.